Sign Up
OverviewAPI
Medtronic's SMART Trial data reveals Evolut TAVR platform superiority over Sapien for treating severe aortic stenosis, especially beneficial for women with small aortic annuli. The trial emphasizes tailored valve selection's crucial role, showing Evolut's non-inferior clinical outcomes and hemodynamic superiority.

Ask a question